{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=86&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Denver",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 7464,
    "total_pages": 747,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=87&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=85&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:22:53.027Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06325683",
      "title": "Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progressive Glioblastoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2024-11-08",
      "completion_date": "2029-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 325,
      "location_summary": "Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Dublin",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06325683"
    },
    {
      "nct_id": "NCT06266494",
      "title": "Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Frostbite"
      ],
      "interventions": [
        {
          "name": "Long-Acting silver dressings",
          "type": "DEVICE"
        },
        {
          "name": "Aloe Vera",
          "type": "OTHER"
        },
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-03-01",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2024-05-13",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06266494"
    },
    {
      "nct_id": "NCT04029922",
      "title": "Study of MT-5111 in HER2-positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Solid Cancers"
      ],
      "interventions": [
        {
          "name": "MT-5111 (experimental study drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-11-12",
      "completion_date": "2023-04-27",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Fullerton, California • Los Alamitos, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04029922"
    },
    {
      "nct_id": "NCT03691831",
      "title": "A Study of A-101 Topical Solution for the Treatment of Common Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Common Wart"
      ],
      "interventions": [
        {
          "name": "Active",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 502,
      "start_date": "2018-09-13",
      "completion_date": "2019-07-09",
      "has_results": true,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 24,
      "location_summary": "Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 21 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03691831"
    },
    {
      "nct_id": "NCT00401245",
      "title": "The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vasomotor Symptoms"
      ],
      "interventions": [
        {
          "name": "desvenlafaxine succinate sustained release",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 500,
      "start_date": "2006-12",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2011-10-26",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 55,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Encinitas, California + 44 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Foothill Ranch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401245"
    },
    {
      "nct_id": "NCT00192439",
      "title": "Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Severe Respiratory Disease"
      ],
      "interventions": [
        {
          "name": "High Risk Respiratory Disease",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "1 Day to 24 Months"
      },
      "enrollment_count": 1500,
      "start_date": "2003-12",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2007-05-07",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 16,
      "location_summary": "Long Beach, California • Denver, Colorado • Chicago, Illinois + 13 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00192439"
    },
    {
      "nct_id": "NCT00002162",
      "title": "A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Saquinavir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Zalcitabine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 140,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002162"
    },
    {
      "nct_id": "NCT03711162",
      "title": "A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "GLPG1690",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lakefront Biotherapeutics NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 525,
      "start_date": "2018-11-28",
      "completion_date": "2021-03-30",
      "has_results": true,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 47,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03711162"
    },
    {
      "nct_id": "NCT03108456",
      "title": "Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Ischemic Heart Disease",
        "Non ST Segment Elevation Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Orbital Atherectomy",
          "type": "DEVICE"
        },
        {
          "name": "Balloon",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2005,
      "start_date": "2017-03-27",
      "completion_date": "2025-06-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 104,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03108456"
    },
    {
      "nct_id": "NCT03530696",
      "title": "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Breast Cancer",
        "Breast Cancer Stage",
        "Recurrent Breast Cancer",
        "Metastatic Breast Cancer",
        "HER2 Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "T-DM1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2018-12-06",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-11-19T08:22:53.027Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03530696"
    }
  ]
}